樂觀
$100.88
情境價格
$57.940
+0.545 (+0.94%)收盤時
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.
Cooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.
Barclays
$60
2026-10-06
Barclays
2026-10-06
目標價
$60
Mizuho
$75
2026-09-11
Mizuho
2026-09-11
目標價
$75
JPMorgan
$58
2026-09-10
JPMorgan
2026-09-10
目標價
$58
Needham
$73
2026-09-10
Needham
2026-09-10
目標價
$73
Citi
$60
2026-09-10
Citi
2026-09-10
目標價
$60
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Rosen Law Firm Investigates Securities Claims Against The Cooper Companies

Rosen Law Firm Investigates Securities Claims Against The Cooper Companies

Kurzius Increases Stake in Cooper Companies

Director Paul A. Keel Acquires $250,000 in Cooper Companies Shares

Cooper Companies Director Increases Stock Holdings
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).
Cooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.
15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。